Search Result

GSK Medical Affairs Portal

Medical Affairs Portal| Portal poświęcony lekom na receptę i szczepionkom GSK. Dedykowany dla lekarzy.

Account Overview – Edit professional details

Account Overview – Edit Password

Account Overview- Edit email address

Account management – Edit personal details

GSK Medical - Please request a contact confirmation Form

Contact us form for UK healthcare professionals to contact GSK

Contact Us Confirmation

Contacte con nosotros para consultas relacionadas con productos o servicios proporcionados por GSK-confirmación

Contact Us Confirmation

Solicite la visita de uno de nuestros delegados de GSK- Confirmación

Herpes Zoster

Herpes zoster, also known as shingles, is a painful condition caused by reactivation of the varicella zoster virus, the same virus that causes chickenpox.1-4

Effect of Camlipixant on Cardiac Repolarization in Healthy Participants: A Thorough QT/QTc Study

ATS Poster

ATS 2025 International Conference

Investigating Camlipixant P2X3 Selectivity and Taste Disturbance: A Model-Based Dose–Response Meta-Analysis

ATS Poster

A Scoping Literature Review of Digital Endpoints for Chronic Cough Over the Past Five Years: Closing the Gap Between Clinical Trials and Real- World Clinical Practice

ATS Poster

OverSEA: European Delphi consensus study on best practices for patients with severe eosinophilic asthma and comorbid CRSwNP

Mepolizumab in patients with asthma and features of COPD: a MENSA/MUSCA post hoc analysis

Evaluating the influence of health policy on health outcomes: REALITI-A post-hoc analysis at 2 years

Effectiveness of mepolizumab on severe asthma in Argentina: a real-world cohort study

Predicting real-world response to mepolizumab in severe asthma using machine learning

Has OCS use for severe asthma decreased in the last 10 years?

Burden of asthma and health care resource utilization in patients with severe asthma and an eosinophilic phenotype: a US claims analysis

Eosinophilic granulomatosis with polyangiitis: clinical suspicion red flags identification by a systematic literature review and multidisciplinary expert consensus Arismendi E, et al. Poster PA4015

Decreased number of uncontrolled severe asthma patients while need of OCS reduction remains: RWE data analysis in Germany 2022 vs 2019

Clinical trial design of biologic therapies in COPD: MATINEE study of mepolizumab Pavord I, et al. Poster PA4789

Understanding the burden of EGPA - Medical symposium EULAR 2024

Medical Affairs Portal| Portal poświęcony lekom na receptę i szczepionkom GSK. Dedykowany dla lekarzy.

Untangling the immunological basis of EGPA - Medical symposium EULAR 2024

Medical Affairs Portal| Portal poświęcony lekom na receptę i szczepionkom GSK. Dedykowany dla lekarzy.

The relevance of IL-5 biology in severe asthma - Medical symposium EAACI 2024

Medical Affairs Portal| Portal poświęcony lekom na receptę i szczepionkom GSK. Dedykowany dla lekarzy.

Optimising EGPA treatment: Translating data into clinical practice - Medical symposium EULAR 2024

Medical Affairs Portal| Portal poświęcony lekom na receptę i szczepionkom GSK. Dedykowany dla lekarzy.

The evolving understanding of IL-5 biology - Medical symposium EAACI 2024

Medical Affairs Portal| Portal poświęcony lekom na receptę i szczepionkom GSK. Dedykowany dla lekarzy.

Clinical implications of biologic therapies in comorbid severe asthma and CRSwNP - Medical symposium EAACI 2024

Medical Affairs Portal| Portal poświęcony lekom na receptę i szczepionkom GSK. Dedykowany dla lekarzy.

The relevance of IL-5 biology in CRSwNP - Medical symposium EAACI 2024

Medical Affairs Portal| Portal poświęcony lekom na receptę i szczepionkom GSK. Dedykowany dla lekarzy.

Depemokimab efficacy/safety in patients with asthma on medium/high- dose ICS: the Phase IIIA randomised SWIFT-1/2 studies.

Enhanced in vitro potency of depemokimab for interleukin-5 inhibition versus mepolizumab.

SWIFT-1 and SWIFT-2 Study Design: Replicate Phase 3A Randomized, Double-Blind, Placebo-Controlled, Multicenter Studies of the Efficacy and Safety of Depemokimab in Patients With Asthma With an Eosinophilic Phenotype

Patients' perspectives and perceptions of asthma clinical remission: a global view. Valliant SN, et al. Poster PA1183

Phase I, single-dose study to compare pharmacokinetics of depemokimab delivered by safety syringe device or autoinjector in healthy adults

ANCHOR-1 and 2 Study Design: Replicate Phase 3 Randomized, Double-Blind, Placebo-Controlled Studies of the Efficacy and Safety of Depemokimab in Patients with Chronic Rhinosinusitis with Nasal Polyps

Real-world effectiveness of mepolizumab in patients with severe asthma with/without chronic rhinosinusitis with nasal polyps: pooled analysis from European cohorts. Palomares I, et al. Poster PA3929

Depemokimab PK/PD in the 52-week randomised double-blind multicentre Phase III SWIFT-1 trial.

Clinical characteristics impacting clinical remission attainment in REALITI-A , Brusselle G, et al. PA1200

Real-world assessment of clinical remission in asthma with biologics Howarth P, et al. Poster PA2182

Reduction of Systemic Corticosteroid (SCS) Related Complications With Mepolizumab in Severe Asthma: A Novel Real-World Outcome Study

Efficacy of Mepolizumab in Patients With COPD With Chronic Bronchitis and Type 2 Inflammation – a Post Hoc Analysis of the METREX & METREO Phase 3 Studies

Towards a Patient-Centric Definition of Asthma Remission: An Interim Analysis of a Multi-Country, Qualitative Study

Evaluation of Clinical Remission Indicators in Asthma Patients Treated With Biologics in a Real-World Setting

Safety of Mepolizumab With 7429 Patient-Years of Exposure: Pooled Analysis From 4175 Patients in 32 Clinical Studies Across Multiple Indications

Efficacy of Mepolizumab in Patients With Chronic Obstructive Pulmonary Disease With or Without Chronic Bronchitis: Post Hoc Analysis of the METREX and METREO Phase 3 Trials

Impact of Half-Life Extension via YTE Modification on the Duration of Action, Efficacy, and Safety of Monoclonal Antibodies: A Systematic Literature Review

Oral Corticosteroid-Sparing Effects of Mepolizumab in Eosinophilic Granulomatosis With Polyangiitis (EGPA): Results up to 7.4 Years From the Long-Term Access Program

Real-World Mepolizumab Use in Eosinophilic Granulomatosis With Polyangiitis (EGPA) Demonstrates Improvement in End-Organ Manifestations and Long-Term Corticosteroid Benefit: An Analysis of Allergy Practices in the United States

Health Care Situation in the Treatment of Uncontrolled GINA 4/5 Asthma Patients in Germany: 2019 vs. 2022

Clinical variables associated with achieving improvement in asthma control with mepolizumab in patients from the REDES study

OverSEA: European Delphi Consensus Study on Best Practices for Patients with Severe Eosinophilic Asthma and Comorbid Chronic Rhinosinusitis with Nasal Polyps

Mepolizumab response in patients with COPD with type 2 inflammation with/without chronic bronchitis (CB): A METREX/METREO post hoc analysis

Impact of Mepolizumab on Exacerbations and Maintenance OCS Use in Patients with Asthma and Baseline Blood Eosinophils counts of in the REALITI-A Study: 2- Year Outcomes

Real-World Change in Asthma Symptom Control and Oral Corticosteroid Use in Patients with Severe Asthma Treated with Mepolizumab Stratified by Atopic Status: Post Hoc Analysis of REALITI-A at 2 years

The MARS study: a single-arm, multi-centre study to assess the long-term (≥96 weeks) safety and effectiveness of mepolizumab in patients with eosinophilic granulomatosis with polyangiitis in Japan

Mepolizumab Simultaneously Improves Clinical Outcomes in CRSwNP and Asthma in the SYNAPSE Study: Focus on Global Airway Disease

Eosinophilic Granulomatosis with Polyangiitis: Clinical Suspicion Red Flags Identification by a Systematic Literature Review and Multidisciplinary Expert Consensus

OCS use in uncontrolled severe asthma in Canada

Long-Term Safety of Mepolizumab in EGPA: Results From the Long-Term Access Programme

Effect of Mepolizumab on airways remodeling in patients with late-onset severe eosinophilic asthma and fixed obstruction (preliminary data of the MESILICO study)

Impact of Mepolizumab on Sleep Disturbance in Patients With Chronic Rhinosinusitis With Nasal Polyps and/or Asthma: Analysis From SYNAPSE and MUSCA

Real-World Effectiveness of Mepolizumab in Patients With Chronic Rhinosinusitis With Nasal Polyps: A Pre/Post Assessment of Oral Corticosteroid Use and Sinus Surgery in the US

Effectiveness of Switching to Mepolizumab from Other Biologics in Asthma Patients: A Real-World Analysis

Patient and Physician Perspectives on Mepolizumab Treatment in Severe Asthma: Data From the REALITI-A Study

A Real-World Study of Mepolizumab in Patients with EGPA and HES: Insights in Rare Eosinophilic Disease

Real-World Characteristics and Clinical Outcomes of European Patients With Hypereosinophilic Syndrome Receiving Biologics in Europe

Clinical Remission Outcome in Patients with Severe Asthma with an Eosinophilic Phenotype (SA-EP) Receiving Mepolizumab: A Post-Hoc Analysis of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial

Profiling Symptomatic and Quality of Life Benefits of Mepolizumab for Patients With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) in the SYNAPSE Trial

Treatment patterns of patients who initiate biologics for severe asthma across USA, Japan, and Europe

Agreement and discrepancies between past prescribing decisions and future prescribing preferences: An EU outlook

Real-world mepolizumab outcomes in severe asthma: REALITI-A post hoc analysis by exacerbation history

Real-world outcomes with mepolizumab in patients with severe asthma and comorbid anxiety/depression: REALITI-A at 2 years

Clinical remission with mepolizumab in severe asthma: impact of lung function parameters

Clinical remission in a real-world study to evaluate mepolizumab effectiveness in treating severe eosinophilic asthma (SEA) in Taiwan (REMIT)

Biologic treatment patterns of severe asthma patients in the EU-4 and the UK

Mepolizumab long-term safety in severe eosinophilic asthma

Patients' knowledge, perspectives and attitudes towards treatment goals and clinical remission in severe asthma

Multi-country self-controlled study of exacerbation rates in severe asthma patients treated with mepolizumab: NEST interim analysis

Real-world outcomes of patients with severe asthma treated with mepolizumab stratified by baseline inhaled corticosteroid dose: Post hoc analysis of REALITI-A at 2 years

Characterisation and burden of eosinophilic granulomatosis with polyangiitis in European patients by disease phase

Additional effects of oral prednisolone following mepolizumab on the nasal transcriptome

Mepolizumab is associated with clinical benefits in patient with chronic rhinosinusitis with nasal polyps, irrespective of prior systemic corticosteroid use

Outcomes of blocking IL-5 in severe asthma elderly patients

Multicentric real life experience of mepolizumab in bronchiectasis concomitant to severe asthma

The prevalence of severe asthma and severe eosinophilic asthma in Finland

Role of Eosinophil Mitochondrial Function in Severe Eosinophilic Asthma

ERS 2024 International Congress

ATS 2024 International Conference

This area of the website is intended for HCPs specializing in Oncology. GSK does not support or endorse any use of its products that is not consistent with the approved prescribing information in the official product monograph

GSK Oncology Medical | Congress Presentations

Medical Affairs Portal| Portal poświęcony lekom na receptę i szczepionkom GSK. Dedykowany dla lekarzy.

Oncology/Hematology

Pharmacokinetics and Pharmacodynamics of Twice Yearly Depemokimab in the Randomized, Double-Blind, Placebo-Controlled Parallel Phase III ANCHOR-1/2 Trials

Low Adherence to Current Biologic Therapies in Asthma: Insights From a Retrospective Cohort Analysis of Claims Data

The impact of mepolizumab self-administration on real-world outcomes in patients with severe asthma: post hoc analysis of REALITI-A at 2 years

Greater Odds of Clinical Remission With Mepolizumab Versus Placebo in Severe Asthma: A 24-Week Individual Patient Data Meta-Analysis of RCTs

Mepolizumab Significantly Reduces Clinical Interventions in the Management of Patients With CRSwNP: Post Hoc Analysis of SYNAPSE Using a Composite Endpoint

Depemokimab Reduces Exacerbations in Patients With Type 2 Asthma Characterized by Blood Eosinophils Across a Range of Blood Eosinophil and IgE Levels: SWIFT Subgroup Analyses

Prior and concomitant medication use in patients with refractory chronic cough: post-hoc analysis of SOOTHE

The Impact of Itraconazole, a Strong CYP3A4 Inhibitor, on the Pharmacokinetics and Safety of Camlipixant in Healthy Participants

Mepolizumab Reduces Systemic Corticosteroid (SCS) Related Toxicities Compared to Chronic SCS Use in Patients With EGPA

Twice-Yearly Depemokimab Demonstrates an Acceptable Safety Profile in a 12-Month Interim Analysis of the AGILE Phase III Open-Label Extension Study

Efficacy of Mepolizumab in Chinese Severe Asthma Patients on Medium-Dose Inhaled Corticosteroids

Benefit of Early Versus Delayed Intervention With Mepolizumab in Patients With Severe Uncontrolled Asthma (SUA): A Retrospective Cohort Study

Mepolizumab Improves Patient Reported Outcomes and Reduces Treatment Burden in Patients With Chronic Rhinosinusitis With Nasal Polyps: A Real-World Chart Review Study

The Impact of Paroxetine, a Strong CYP2D6 Inhibitor, on the Pharmacokinetics and Safety of Camlipixant in Healthy Participants

Mepolizumab Is Efficacious in Patients With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) With One or Multiple Prior Nasal Polyps (NP) Surgeries: SYNAPSE Outcomes

Efficacy and Safety of Twice Yearly Depemokimab in Patients With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP): The Phase III Randomized, Double-Blind, Placebo-Controlled Replicate ANCHOR-1/2 Trials

AAAAI 2025 Annual Meeting

Respiratory

Striving for disease stability in COPD - Medical symposium summary ERS 2024

Medical Affairs Portal| Portal poświęcony lekom na receptę i szczepionkom GSK. Dedykowany dla lekarzy.

Patient management

Treatment options for herpes zoster are suboptimal and may have limited efficacy and poor tolerability in some patients. Therefore, improvements are needed in the prevention and management of herpes zoster.1,2

Epidemiology and risk factors

Herpes zoster is caused by the reactivation of the varicella zoster virus.

Burden of disease and complications

Co-administration of the recombinant zoster vaccine (RZV) with other adult vaccines

Throughout life, vaccines are recommended to protect individuals from vaccine-preventable diseases.

Prevention through vaccination: Immunocompromised patients

Efficacy, immunogenicity, and safety of the adjuvanted recombinant zoster vaccine (RZV) in immunocompromised subjects

Disease Information

View disease information content from GSK Vaccines

Prevention through vaccination: The ZOE programme - RZV pivotal and extension studies in individuals over 50 years of age

The efficacy of the Recombinant Zoster Vaccine (RZV) was evaluated in two Phase 3 clinical trials, Zoster Efficacy Study in Adults 50 Years of Age or Older (ZOE-50, NCT01165177) and Zoster Efficacy Study in Adults 70 Years of Age or Older (ZOE-70, NCT01165229).1,2 The ZOE-LTFU (NCT02723773) is a long-term follow-up (LTFU) study of the ZOE-50 and ZOE-70 pivotal trials.3,4